1. Singh B.N., Singh S.N., Reda D.J. et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352(18):1861-72.
2. Wyse D.G., Waldo A.L., DiMarco J.P. et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347(23):1825-33.
3. Roy D., Talajic M., Dorian P. et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342(13):913-20.
4. Julian D.G., Camm A.J., Frangin G. et al., for the European Myocardial Infarct Amiodarone Trial Investigators: Randomized trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349(9053): 667-674.
5. Cairns J.A., Connolly S.J., Roberts R., Gent M. for the Canadian Amiodarone Myocardial InfarctionArrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent orrepetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349(9053): 675-682.
6. Brunton L., Lazo J., Parker K., editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2005.
7. Melnichenko G.A., Fadeev V.V.,Dedov I.I. Thyroid disease during pregnancy: diagnosis,treatment, prevention (manualfor physicians). Moscow: MedEkspertPress; 2003. Russian. (Мельниченко Г.А., Фадеев В.В., Дедов И.И. Заболевания щитовидной железы во время беременности: диагностика, лечение, профилактика (пособие для врачей). М.: МедЭкспертПресс; 2003).
8. Dunn J.T., Semigran M.J., Delange F. The prevention and management of iodine-induced hyperthyroidism and its cardiac features. Thyroid 1998;8(1):101-6.
9. Chazov E.I., Dedov I.I., eds. Cardiac and endocrine aspects of the use of amiodarone in the modern practice of treating cardiac arrhythmias. Manual. Moscow: Prototip; 2005. Russian. (Чазов Е.И., Дедов И.И., редакторы. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритма сердца. Методическое пособие. М.: Прототип; 2005).
10. Naccarelli G.V., Rinkenberger R.L.,DoughertyA.H., Giebel R.A. Amiodarone: pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy. 1985; 5(6): 298-313.
11. Shulutko B.I., Makarenko S.V. Standards for diagnosis and treatment of internal diseases. St. Petersburg: ELBI-SPb; 2007. S.73-83. Russian. (Шулутко Б.И., Макаренко С.В. Стандарты диагностики и лечения внутренних болезней. СПб.: ЭЛБИ-СПб; 2007. С.73-83).
12. Connolly S.J. Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation 1999;100(19): 2025-34.
13. Amiodarone Trials Meta-Analyssis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350(9089): 1417-24.
14. Brendorp B., Torp-Pedersen C., Elming H., Køber L. Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. Eur Heart J 2003; 24(3):274-9.
15. McNamara R.L., Tamariz L.J., Segal J.B., Bass E.B. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139(12): 1018-1033.
16. Hohnloser S.H., Crijns H.J., van Eickels M. et al. for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360(7): 668-78.
17. Køber L., Torp-Pedersen C., McMurray J.J. et al. Increased Mortality after Dronedarone Therapy for Severe Heart Failure. N Engl J Med 2008;358(25):2678-87.
